The antiserum was produced against synthesized peptide derived from human Cyclin D1 around the phosphorylation site of Thr286. AA range:246-295

Phospho-Cyclin D1 (T286) Polyclonal Antibody detects endogenous levels of Cyclin D1 protein only when phosphorylated at T286.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):ACtPT

CCND1

G1/S-specific cyclin-D1

CCND1 ;
BCL1 ;
PRAD1 ;
G1/S-specific cyclin-D1 ;
B-cell lymphoma 1 protein ;
BCL-1 ;
BCL-1 oncogene ;
PRAD1 oncogene

The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. [provided by RefSeq, Jul 2008],

Disease:A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.,Disease:A chromosomal aberration involving CCND1 may be a cause of multiple myeloma [MIM:254500]. Translocation t(11;14)(q13;q32) with the IgH locus.,Disease:A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas [MIM:168461]. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.,Function:Essential for the control of the cell cycle at the G1/S (start) transition.,online information:The Singapore human mutation and polymorphism database,PTM:Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest.,PTM:Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.,similarity:Belongs to the cyclin family.,similarity:Belongs to the cyclin family. Cyclin D subfamily.,subunit:Interacts with the CDK4 and CDK6 protein kinases to form a serine/threonine kinase holoenzyme complex. The cyclin subunit imparts substrate specificity to the complex.,

Nucleus . Cytoplasm . Nucleus membrane . Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members. .

>>Endocrine resistance ;
>>FoxO signaling pathway ;
>>Cell cycle ;
>>p53 signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>AMPK signaling pathway ;
>>Cellular senescence ;
>>Wnt signaling pathway ;
>>Hedgehog signaling pathway ;
>>Apelin signaling pathway ;
>>Hippo signaling pathway ;
>>Focal adhesion ;
>>Tight junction ;
>>JAK-STAT signaling pathway ;
>>Prolactin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Oxytocin signaling pathway ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Cushing syndrome ;
>>Alcoholic liver disease ;
>>Hepatitis C ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Human papillomavirus infection ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Epstein-Barr virus infection ;
>>Pathways in cancer ;
>>Viral carcinogenesis ;
>>Proteoglycans in cancer ;
>>MicroRNAs in cancer ;
>>Chemical carcinogenesis - receptor activation ;
>>Colorectal cancer ;
>>Pancreatic cancer ;
>>Endometrial cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Thyroid cancer ;
>>Melanoma ;
>>Bladder cancer ;
>>Chronic myeloid leukemia ;
>>Acute myeloid leukemia ;
>>Small cell lung cancer ;
>>Non-small cell lung cancer ;
>>Breast cancer ;
>>Hepatocellular carcinoma ;
>>Gastric cancer ;
>>Viral myocarditis